Evidence map›Paper›PMID 39358745›Full record

ArticleBMC medicine2024

The association between serum S100β levels and prognosis in acute stroke patients after intravenous thrombolysis: a multicenter prospective cohort study.

Yang Qu, Hang Jin, Reziya Abuduxukuer, Shuang Qi, Xiang-Kun Si, Peng Zhang, Ke-Jia Zhang, Si-Ji Wang, Xiang-Yu Zheng, Yu Zhang and 23 more

Abstract readMulticenter Study
In one paragraph

Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. S-100B in acute ischemic stroke: a visualization of global hotspots.International journal of emergency medicine · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Yang QuStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Hang JinStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Reziya AbuduxukuerStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Shuang QiStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Xiang-Kun SiStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Peng ZhangStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Ke-Jia ZhangStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Si-Ji WangStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Xiang-Yu ZhengDepartment of Neurology, the First Hospital of Jilin University, Changchun, China.
Yu ZhangDepartment of Neurology, Songyuan Central Hospital, Songyuan, China.
Jian-Hua GaoDepartment of Neurology, Jilin Neuropsychiatric Hospital, Siping, China.
Xian-Kun ZhangStroke Center, Department of Neurology, Siping Central People's Hospital, Siping, China.
Xiao-Dong LiuDepartment of Neurosurgery, Tonghua City Vascular Disease Hospital and Dongchang District People's Hospital, Tonghua, China.
Chun-Ying LiDepartment of Neurology, Songyuan Jilin Oilfield Hospital, Songyuan, China.
Guang-Cai LiStroke Center, Department of Neurology, Dehuishi People's Hospital, Changchun, China.
Junmin WangDepartment of Neurology, Affiliated Hospital of Jilin Medical College, Jilin, China.
Huimin JinDepartment of Neurology, Songyuan Hospital of Integrated Traditional Chinese and Western Medicine, Songyuan, China.
Ying HeStroke Center, Department of Neurology, Qianguoerros Mongolian Autonomous County Hospital, Songyuan, China.
Ligang JiangDepartment of Neurology, Affiliated Hospital of Jilin Medical College, Jilin, China.
Liang LiuDepartment of Neurology, Jilin City Hospital of Chemical Industry, Jilin, China.
Yongfei JiangDepartment of Neurology, Changchun People's Hospital, Changchun, China.
Rui-Hong TengDepartment of Neurology, Dongliao First People's Hospital, Liaoyuan, China.
Yan JiaDepartment of Neurology, Jilin People's Hospital, Jilin, China.
Bai-Jing ZhangDepartment of Neurology, Jilin City Hospital of Chemical Industry, Jilin, China.
Zhibo ChenDepartment of Neurology, Jilin City Hospital of Chemical Industry, Jilin, China.
Yingbin QiDepartment of Neurology, Jilin Province People's Hospital, Changchun, China.
Xiuping LiuStroke Center, Department of Neurology, Jilin Central General Hospital, Jilin, China.
Song LiDepartment of Neurology, Jilin Province People's Hospital, Changchun, China.
Xin SunStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Thanh N NguyenBoston Medical Center Neurology, Radiology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, USA.
Yi YangStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China. yang_yi@jlu.edu.cn.
Zhen-Ni GuoStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China. zhen1ni2@jlu.edu.cn.
Biomarkers of Brain Injury Investigator Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundS100β is a biomarker of astroglial damage, the level of which is significantly increased following brain injury. However, the characteristics of S100β and its association with prognosis in patients with acute ischemic stroke following intravenous thrombolysis (IVT) remain unclear.

methodsPatients in this multicenter prospective cohort study were prospectively and consecutively recruited from 16 centers. Serum S100β levels were measured 24 h after IVT. National Institutes of Health Stroke Scale (NIHSS) and hemorrhagic transformation (HT) were measured simultaneously. NIHSS at 7 days after stroke, final infarct volume, and modified Rankin Scale (mRS) scores at 90 days were also collected. An mRS score ≥ 2 at 90 days was defined as an unfavorable outcome.

resultsA total of 1072 patients were included in the analysis. The highest S100β levels (> 0.20 ng/mL) correlated independently with HT and higher NIHSS at 24 h, higher NIHSS at 7 days, larger final infarct volume, and unfavorable outcome at 3 months. The patients were divided into two groups based on dominant and non-dominant stroke hemispheres. The highest S100β level was similarly associated with the infarct volume in patients with stroke in either hemisphere (dominant: β 36.853, 95% confidence interval (CI) 22.659-51.048, P < 0.001; non-dominant: β 23.645, 95% CI 10.774-36.516, P = 0.007). However, serum S100β levels at 24 h were more strongly associated with NIHSS scores at 24 h and 3-month unfavorable outcome in patients with dominant hemisphere stroke (NIHSS: β 3.470, 95% CI 2.392-4.548, P < 0.001; 3-month outcome: odds ratio (OR) 5.436, 95% CI 2.936-10.064, P < 0.001) than in those with non-dominant hemisphere stroke (NIHSS: β 0.326, 95% CI  - 0.735-1.387, P = 0.547; 3-month outcome: OR 0.882, 95% CI 0.538-1.445, P = 0.619). The association of S100β levels and HT was not significant in either stroke lateralization group.

conclusionsSerum S100β levels 24 h after IVT were independently associated with HT, infarct volume, and prognosis in patients with IVT, which suggests the application value of serum S100β in judging the degree of disease and predicting prognosis.

Indexed as

S100 Calcium Binding Protein beta SubunitStrokeThrombolytic TherapyAdministration, IntravenousAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPrognosisProspective StudiesTreatment OutcomeBiomarkersS100B protein, humanS100 Calcium Binding Protein beta SubunitAcute ischemic strokeAstroglial injuryIntravenous thrombolysisOutcomeS100β

Identifiers

PMID39358745
PMCPMC11447957

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.